Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of inciden-
Introduction
Non-alcoholic fatty liver disease (NAFLD), encompassing both simple steatosis and non-alcoholic steatohepatitis (NASH), is a condition characterised by excessive fat accumulation in the liver in the presence of metabolic risk factors and the absence of significant alcohol intake, or other causes of hepatic steatosis. The diagnosis of NASH relies upon a liver biopsy to demonstrate liver cell injury and inflammation. The prevalence of NAFLD is increasing in association with the widespread presence of obesity and type 2 diabetes 1, 2 and is now the most common cause of incidental liver test abnormalities in primary care. 3 A study of over 1000 adult patients from eight primary care practices in the UK reported that abnormal liver function tests were commonly found incidentally during routine review of other chronic diseases, such as diabetes, cardiovascular disease and hypertension, and that NAFLD accounted for over 25% of cases. 3 Of concern, a study from a single Veterans Administration primary care centre showed that most patients at high risk of NAFLD were not being acknowledged or evaluated for this condition. 4 Among 251 patients with NAFLD identified by the study investigators, only 21.5% had a diagnosis of NAFLD in primary care, 14.7% were counselled about diet and exercise and 10.4% were referred to a specialist. 4 The study found that the only factors associated with receiving NAFLD-related care were the magnitude (with at least one alanine aminotransferase (ALT) value >80 IU/mL) and proportion (where ≥50% of a patient's ALT values were >40 IU/mL) of ALT elevation. 4 Among people with NAFLD, recognition of advanced liver fibrosis is important because these patients may require specialist care and surveillance for liver cancer and liver decompensation. Most people with NAFLD have traditional normal-range liver blood tests 5 and liver enzyme levels do not reflect the presence or severity of necroinflammation or fibrosis. 6, 7 The recently released UK National Institute of Clinical Excellence guidelines (NAFLD: assessment and management) advocate that routine liver blood tests alone should not be used to rule out NAFLD nor identify advanced fibrosis in people with NAFLD. 8 Clinical practice guidelines for the diagnosis and management of NAFLD produced by international subspecialist committees 9 recommend that '… Surrogate markers of fibrosis (NAFLD fibrosis score (NFS), Fibrosis 4 test (FIB-4), Enhanced Liver Fibrosis (ELF) test or FibroTest) should be calculated for every NAFLD patient, in order to rule out significant fibrosis (≥F2). If significant fibrosis cannot be ruled out, patients should be referred to a Liver Clinic for transient elastography …'. 9 Both the NFS and FIB-4 have a high negative predictive value, 10 are low to no cost as they are calculated from routine blood tests (platelets, albumin, ALT and aspartate aminotransferase (AST)), age and body mass index (BMI) and can be run repeatedly without additional costs. The commercially available ELF test is calculated from combining three measured direct markers of liver matrix metabolism in serum. The ELF panel has good diagnostic accuracy for advanced fibrosis 11, 12 and has been shown to predict disease progression 13 and the development of liver-related clinical events in patients with chronic liver disease. 13, 14 In Australia, the FibroTest is currently only available in a research capacity. Transient elastography (TE) provides a non-invasive assessment of liver fibrosis; however, this technology is not ideal for stratifying liver disease severity in the community, as it requires specialist expertise to obtain and interpret data.
Primary care clinicians have a key role in identifying patients with NAFLD who are at risk of significant liver disease and who may require specialist referral for further evaluation, or closer management of metabolic comorbidities and lifestyle interventions. However, it is currently unclear whether GP are aware of the recommendations regarding NAFLD risk stratification and management. We have previously shown that fatty liver and abnormal liver tests accounted for around 10% of referrals for hepatology outpatient consultation at a major tertiary referral hospital. 15 Clinical information provided by referring clinicians was often incomplete and only a minority of referrals provided information about BMI or alcohol intake. 15, 16 There are no current Australian guidelines for NAFLD management in primary care, although the RACGP website (http://www. racgp.org.au/afp/2013/july/fatty-liver-disease/) contains a practical guide and algorithm for management of suspected NAFLD. 17 The purpose of this study was to assess primary care clinicians' current understanding of NAFLD, along with their approach to diagnosis, management and criteria for referral. In order to address this, a cross-sectional survey of primary care clinicians from the greater Brisbane area was undertaken through a structured questionnaire about NAFLD.
Methods
A cross-sectional study was conducted in south-east Queensland between August 2016 and March 2017. A convenience sample of general practice clinics and general practice conferences in metropolitan Brisbane and regional south east Queensland were selected. All primary care clinicians who attended general practice unit meetings or the conferences were invited to participate in the study.
The self-administered structured survey (available on request) developed by a research group (comprised of a hepatologist, epidemiologist and GP) for this study consisted of a series of closed-ended questions and one open-ended question. The survey was divided into four parts: (i) a brief introductory paragraph defining NAFLD and the spectrum of disease, including simple steatosis and NASH; (ii) a short demographic section comprising variables, such as Practice postcode, level of appointment, an estimate of the number of different patients seen per week, and an estimate of the proportion of subjects with NAFLD within their patient population; (iii) questions assessing the respondents' knowledge about the prevalence of NAFLD, risk factors and perceptions about morbidity, diagnosis, risk stratification and treatment and (iv) respondents were asked about the referrals they made to hepatology services for investigation or management of NAFLD/NASH.
Face and content validity of the survey was assessed by delivering the questionnaire to three GP to determine whether they understood the questions and thought that the content of questions was relevant. Retest reliability was not assessed as it was not feasible to deliver the questionnaire to the same primary care clinicians twice due to their busy schedules.
This study was approved by the Princess Alexandra Hospital and The University of Queensland Human Research Ethics Committees (HREC/15/QPAH/301; UQ:2015001047).
Statistical methods
Basic descriptive details (total numbers and percentages) are presented. Continuous variables were summarised as mean (standard error of the mean) and median (range). The Chi-squared test was used to compare categorical variables and Student's t-test to compare continuous variables. SPSS version 24.0 (SPSS, Chicago, IL, USA) was used for all analyses and a value of P < 0.05 was considered statistically significant. Microsoft Excel (Microsoft Office Professional Plus 2010, Redmond, WA, USA) was used to conduct inductive thematic analysis, classifying qualitative data obtained through an open-ended question into meaningful answers. The proportion of respondents reporting the most common responses was described.
Results

Demographic characteristics of the survey respondents
The survey was completed by 108 primary care clinicians. Of these, 87 were GP, 7 were GP registrars, 9 were practice nurses and 5 did not provide their level of appointment. The respondents' practices were located in metropolitan Brisbane (n = 68), regional/remote Queensland (n = 30), locum positions or outside Queensland (n = 5) and five respondents did not provide their Practice post-code. A surveyor was present during administration of the survey and the participation rate was 100%. Six respondents completed less than 50% of the survey and were excluded from all further analyses. The remainder of the respondents completed >65% of the survey. The median number of different patients seen by a respondent each week was 80.
Characteristics of the patient populations
Overall, respondents estimated that 15.5 AE 13.5% of their patient population had type 2 diabetes, 19.1 AE 13.1% had dyslipidaemia or hypertriglyceridaemia, 21.7 AE 14.4% had hypertension, 28.6 AE 17.2% were overweight or obese and 16.6 AE 12.2% consumed excess alcohol. A substantial proportion of the respondents indicated that NAFLD was not common among their patients, with 38.2% estimating the prevalence to be ≤10% (Fig. 1) . There was no statistical difference in the estimated prevalence of NAFLD/NASH or metabolic comorbidities between rural and metropolitan regions (data not presented, P > 0.05).
Awareness of prevalence of and factors associated with NAFLD/NASH
Overall, 51% of respondents considered the prevalence of NAFLD in the general population to be ≤10% ( Fig. 2A) and 54% of primary care clinicians considered the prevalence of NAFLD in the obese population to ≤50% (Fig. 2B ). There was no significant difference between metropolitan and rural practitioners' responses (data not presented, P > 0.05).
More than 90% of respondents recognised that overweight/obesity, type 2 diabetes, metabolic syndrome and hypertriglyceridaemia were strongly associated with NAFLD. Half of the respondents (51.0%) considered that hypertension was associated with NAFLD, and most (73.5%) considered alcohol consumption to be strongly 
Perception of morbidity/mortality associated with NAFLD
Respondents were aware that simple steatosis is associated with an increased incidence of cardiovascular disease (65.7%), and future development of type 2 diabetes (73.5%). In contrast, the relative absence of liver-related outcomes associated with simple steatosis was not as well appreciated. 61.8% of respondents considered that simple steatosis is associated with increased liver-related mortality and 47.1% considered these subjects at significantly higher risk of cirrhosis. Most respondents were aware of the increased risk of cirrhosis and liver-related mortality in subjects with NASH (71.6 and 75.5% respectively).
Perception of tests for diagnosis and risk stratification of NASH
Many primary care clinicians incorrectly felt that a diagnosis of NASH can be made using serum liver enzymes (52.9%), liver imaging (70.6%) or FibroScan (62.7%). Of concern, 24.5% of respondents felt that liver enzymes (ALT and AST) are sufficiently sensitive to detect underlying NAFLD-NASH and a further 25.5% were unsure.
The majority of respondents agreed that liver enzymes (ALT, AST) (79.4%), platelet count (67.6%), serum albumin (80.4%), prothrombin time (69.6%), NAFLD Fibrosis score (81.4%), abdominal ultrasound (77.5%) and FibroScan (71.6%) can help to identify NAFLD patients with advanced fibrosis/cirrhosis. However, most respondents were unsure whether the FIB-4 score (62.7% unsure) or ELF score (63.7% unsure) could help to identify advanced fibrosis or cirrhosis.
Although 87.3% of respondents felt that 6 monthly liver enzyme tests can help to monitor disease progression in patients with NAFLD, there was less clarity about the use of other tests. Many clinicians were unsure whether platelet count (26.5% unsure), FibroScan (36.3%), NAFLD Fibrosis score/Fib-4 test (43.1%) or the ELF test (56.9%) can help to monitor disease progression.
Assessment of clinical and referral practice
Respondents were asked whether they utilise certain tools in their clinical practice to assess their patients with NAFLD (Fig. 3) . A total of 92 and 87.3% use liver enzymes and abdominal ultrasound, respectively, for NAFLD assessment. However, the majority of clinicians do not use FibroScan (80.4%), NAFLD Fibrosis score (76.5%), Fib-4 score (85.3%), AST to Platelet Ratio Index (APRI) score (78.4%) or ELF test (74.5%).
With respect to clinical management, the majority of clinicians would provide information on optimising diet and exercise (94.1%), provide a GP management plan and team care arrangements (74.5%) and refer to a dietician (90.2%). Forty-seven percent of respondents stated that they would refer a patient to a Gastroenterologist/Hepatologist if they suspect the patient has NAFLD. Despite this, when asked how many referrals they make to Hepatology each month for an opinion regarding suspected NAFLD/NASH, 44.1% do not make any referrals and a further 44.1% make less than 1-2 referrals each month (Fig. 4) . Common reasons provided for not referring patients to Hepatology included: 'The patients do not want referral' (18.8%), 'There is no specific pharmacotherapy available' (6.3%), 'I manage them myself by optimising lifestyle' (38.5%), 'The waiting list is too long' (12.5%), 'I don't see many patients with NAFLD/NASH' (31.3%), 'I do not think it is necessary' (4.2%). Of concern, 70.6% of clinicians said they were unlikely to refer a patient to Hepatology unless liver function tests are abnormal. A total of 22 respondents volunteered additional written comments, of whom 31.8% highlighted their own lack of knowledge regarding NAFLD, for example 'After doing this survey I realise I don't know very much about this important topic…'. 
Underappreciation of NAFLD in primary care
Internal Medicine Journal 48 (2018) 144-151
Discussion
Primary care clinicians have a key role in the initial identification and management of NAFLD and in recognising patients at risk of significant liver disease, who may require specialist referral for further evaluation. Recent clinical guidelines have emphasised the use of fibrosis algorithms or serum biomarkers rather than routine liver blood tests, to assess advanced fibrosis in people who have been diagnosed with NAFLD. The present study indicated that the majority (>85%) of primary care clinicians do not use TE, fibrosis biomarkers or algorithms in their clinical practice, to assess their patients with NAFLD. In addition, the majority of clinicians (70.6%) said they were unlikely to refer a NAFLD patient for a Hepatology opinion unless liver function tests are abnormal. These findings are concerning because liver enzyme levels do not correlate with histological findings 7 and reliance on abnormal liver tests may fail to identify patients with significant liver disease. 10 Similar to our findings, a recent survey among 64 GP in The Netherlands found that serum markers/scores were never (73%) or rarely (22%) used to assess NAFLD/NASH and referral to specialist care was highly dependent on elevated liver tests. 18 Not surprisingly, the authors found that GP were not familiar with NAFLD clinical practice guidelines prepared by the hepatology medical societies. 18 Most of the liver-related morbidity and mortality associated with NAFLD occurs in patients with advanced fibrosis, who are at risk of developing complications of end- stage liver disease and hepatocellular carcinoma. 19 Assessment for liver fibrosis within primary care is important to determine prognosis, monitor disease progression and to decide if and when to refer to specialist care. At present, a practical approach to NAFLD diagnosis and staging in the community is recommended, using locally available tests. 20 These include simple non-invasive fibrosis algorithms (NAFLD fibrosis and FIB-4 scores), commercial non-invasive fibrosis tests (the Enhanced Liver Fibrosis test), liver ultrasound and TE (if available). In patients with NAFLD, liver stiffness measurements (LSM) have a high negative predictive value and a modest positive predictive value for detecting advanced fibrosis.
21 Table 1 summarises the components of locally available risk stratification tools and their interpretation.
Our findings demonstrate that many primary care clinicians underestimate the overall prevalence of NAFLD in their community. Approximately half of respondents considered the prevalence of NAFLD in the general population to be ≤10 and 38.2% considered the prevalence of NAFLD in their patient population to be ≤10%. These perceptions conflict with recent reports estimating that GP are likely to encounter more than 300 cases of NAFLD for every 1000 patients that are seen. 22 In a recent large, population-based study from The Netherlands (n = 3041 individuals ≥45 years), 32.8% of participants had evidence of NAFLD on ultrasonography, in the absence of secondary causes of steatosis. 23 Clinically relevant fibrosis (defined by LSM ≥8 kPa) was present in 8.4% of the NAFLD subgroup and in 17.2% of participants with both diabetes and steatosis. 23 Underappreciation of the prevalence of NAFLD may contribute to many affected individuals remaining undiagnosed, in part because the condition is usually asymptomatic and associated with relatively normal or only mildly elevated liver enzyme levels.
Our findings also demonstrate lack of recognition of the clinical spectrum of NAFLD and how this is assessed. NAFLD represents a spectrum of disease from bland steatosis to the necro-inflammatory form, NASH, which is characterised by inflammation and cellular damage (hepatocyte ballooning). Although fibrosis may develop in both steatosis and NASH, fibrosis progression occurs at a more rapid rate in patients with NASH. 24 A metaanalysis of NAFLD studies assessing paired liver biopsies found that on average, fibrosis progressed by 1 stage over 7.1 years for patients with NASH and by 1 stage over 14.3 years for patients with bland steatosis. 24 In this survey, >50% of respondents incorrectly considered that a diagnosis of NASH could be made using serum liver enzymes, liver imaging and/or FibroScan. The diagnosis of NASH requires a liver biopsy, because clinical features, biochemical or imaging tests cannot distinguish steatohepatitis from bland steatosis, and non-invasive tests are not currently validated for this purpose. 9 Recent data from longitudinal studies suggest that fibrosis stage, rather than the presence of NASH, is the most important histological feature associated with liver-related outcome. 19, 25, 26 
Conclusion
Despite recognition that these patients are at risk of progressive liver disease, approximately 45% of primary 
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Internal Medicine Journal 48 (2018) 144-151care clinicians do not make any referrals to hepatology services for an opinion regarding suspected NAFLD/ NASH. This may result in many affected subjects remaining undiagnosed, consequently leading to patients presenting late with decompensated cirrhosis or hepatocellular cancer. Indeed, we have previously shown up to 46% of new referrals for NAFLD can present with advanced disease. 27 Recognition of subjects with early or compensated cirrhosis is important, as these patients require surveillance for the development of gastroesophageal varices and hepatocellular cancer. Several respondents volunteered written comments on the questionnaire form referring to their perceived lack of knowledge regarding NAFLD. In surveys from The Netherlands 18 and an urban western US population,
28
84% of GP and 83% of largely primary care providers, respectively, endorsed the need for increased awareness and knowledge on NAFLD. Our Australian data in conjunction with others, support the global need for educational strategies to improve the recognition and assessment of NAFLD by primary care clinicians. Practical approaches to address this include the provision of educational workshops to increase recognition. 22 Another approach would be to utilise existing models of care to improve patient management by upskilling primary care practices. 29 
